ArticleTherapeutic advances in drug safety2025
A hybrid simulation model of HIV program interventions: from transmission behavior to macroeconomic impacts.
Article in Therapeutic advances in drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How is AI developing in pharmacovigilance?Therapeutic advances in drug safety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Considerable progress has been made in the estimation of drug safety treatment effects-particularly with observational medical claims and electronic medical record data. The use of the Target Trial framework, along with developments in statistical methodology such as doubly robust and G-estimation methods, has improved the ability to draw reliable causal inferences about drug and vaccine safety from observational data. However, such models rarely relate drug safety outcomes to other domains such as economic impacts. As shown by the COVID-19 pandemic, this is a significant limitation with potentially serious and long-term consequences. Objective: The goal of this paper is to demonstrate that the availability of simulation tools would enable policy-makers to assess drug safety and effectiveness outcomes associated with alternative policies, as well as examine these effects in the context of other domains, such as economic outcomes. Design: We develop an agent-based simulation model (ABM) of a peer navigator program to support engagement in HIV therapy in Tanzania. Results from the ABM are weighted to reflect the Tanzanian population and fed into the SPECTRUM model. This generates detailed demographic forecasts that are translated into macroeconomic impacts using labor force participation rates from the International Labor Organization, along with an econometric model of gross domestic product. Results: The ABM simulation estimated that the peer navigation program increased ART participation for men and women by about 12%-15% with no strong trend over time. The impact on VLS, however, was cumulative and significant for both men and women. By year 3, VLS was improved by 33.9 percentage points for women and 32.6 percentage points for men. However, the overall impact of these estimates on mortality was modest-ranging from less than 500 lives per year at the start of the forecast period to about 2500 lives per year in 2030. Consequently, the associated macroeconomic impacts were also small. The relatively modest impacts were due to the limited opportunity for HIV control in Tanzania, which had already met its 95/95/95 goals. Conclusion: Although the simulated macroeconomic effects of the peer navigator program in Tanzania were modest, the paper demonstrates the feasibility of linking behavioral ABM simulations of program impacts to subsequent demographic effects and, finally, macroeconomic performance. Moreover, given the clinical response in ART and VLS in the exposed population in Tanzania, it is likely that the same peer navigator intervention conducted in another country with a larger at-risk HIV population would be much larger.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.